MedElevator
Войти в исследования Minerva pediatrics · 2022
Hypermagnesemia in preterm neonates exposed to antenatal magnesium sulfate.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Correia Ana L, Castro Carolina, Morais Joana M, Portela Alexandrina, Peixoto Sara
Аннотация
BACKGROUND: One of the possible adverse outcomes of magnesium sulfate (MgSO<inf>4</inf>) administration for preterm fetal neuroprotection is hypermagnesemia in the newborn. The objectives of this study were to evaluate the association between antenatal MgSO<inf>4</inf> administration for neuroprotection and neonatal serum magnesium levels in the first days of life.
METHODS: A single-center retrospective case-control study was conducted on preterm neonates born in our institution between January 2017 and December 2019. Prenatal, perinatal, and postnatal parameters were recorded, and demographic information was collected. Comparative analysis between the group of neonates exposed to antenatal MgSO<inf>4</inf> and the control group was performed.
RESULTS: A total of 98 patients were enrolled in the study, 49 of them were exposed to antenatal MgSO<inf>4</inf> for neuroprotection. The serum magnesium levels in the 5 first days of life were higher in the case group, and higher than the normal range of serum magnesium levels (>2.4 mg/dL), with a statistical significance. The number of days needed to normalize serum magnesium levels was higher in the case group compared to the control group (median of 7 days [1-8] versus 2 days [1-5]).
CONCLUSIONS: Our findings show that antenatal administration of MgSO<inf>4</inf> is associated with high serum magnesium levels in neonates. This group of patients needs close electrolyte monitoring during the first days of life. Parenteral nutrition supplemented with magnesium should only be considered after evaluation of serum magnesium levels.
METHODS: A single-center retrospective case-control study was conducted on preterm neonates born in our institution between January 2017 and December 2019. Prenatal, perinatal, and postnatal parameters were recorded, and demographic information was collected. Comparative analysis between the group of neonates exposed to antenatal MgSO<inf>4</inf> and the control group was performed.
RESULTS: A total of 98 patients were enrolled in the study, 49 of them were exposed to antenatal MgSO<inf>4</inf> for neuroprotection. The serum magnesium levels in the 5 first days of life were higher in the case group, and higher than the normal range of serum magnesium levels (>2.4 mg/dL), with a statistical significance. The number of days needed to normalize serum magnesium levels was higher in the case group compared to the control group (median of 7 days [1-8] versus 2 days [1-5]).
CONCLUSIONS: Our findings show that antenatal administration of MgSO<inf>4</inf> is associated with high serum magnesium levels in neonates. This group of patients needs close electrolyte monitoring during the first days of life. Parenteral nutrition supplemented with magnesium should only be considered after evaluation of serum magnesium levels.